atorvastatin has been researched along with sirolimus in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egbert, M; Keserű, GM; Vajda, S; Whitty, A | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W | 1 |
| Barshes, NR; Goodpastor, SE; Goss, JA | 1 |
| Archer, SL; Bonnet, S; Haromy, A; McMurtry, MS; Michelakis, ED | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Ahn, CM; Hong, SJ; Kim, KA; Kim, YH; Lim, DS; Park, JS; Park, JY; Park, SM; Shim, WJ | 1 |
| Ballarín, J; Bestard, O; Carrera, M; Cruzado, JM; Díaz, M; Fulladosa, X; Grinyó, JM; Ibernón, M; Navarro, I; Poveda, R; Romero, R; Torras, J | 1 |
| Foulet-Rogé, A; Gagnadoux, F; Goupil, F; Kernaonet, E; Lebas, FX; Molinier, O; Paris, A | 1 |
| Chen, L; Guo, L; Li, R; Li, Z; Liu, J; Niu, X; Ping, M; Xie, X | 1 |
| Arbeiter, D; Begunk, R; Grabow, N; Hussner, J; Kroemer, HK; Meyer zu Schwabedissen, HE; Petersen, S; Reske, T; Schmitz, KP; Senz, V; Sternberg, K | 1 |
| Atochina-Vasserman, EN; Goncharov, DA; James, ML; Krymskaya, VP; Milavec, M; Volgina, AV | 1 |
| Avihingsanon, Y; Chancharoenthana, W; Praditpornsilpa, K; Somparn, P; Townamchai, N; Vadcharavivad, S; Wanitchanont, A | 1 |
| Al-Rashed, F; Boyle, JJ; Calay, D; Cole, J; Dryden, N; Dumont, O; Hamdulay, SS; Haskard, DO; Holla, VR; Hoong, C; Kiprianos, AP; Liu, Z; Mason, JC; Randi, AM; Shamsi, A; Thornton, CC; Wang, B | 1 |
| Binder, LB; Constantino, LC; Dal-Cim, T; Ludka, FK; Rodrigues, AL; Tasca, CI; Zomkowski, A | 1 |
| Breborowicz, A; Kawka, E; Korybalska, K; Witowski, J | 1 |
| Krishnan, UM; Roopmani, P | 1 |
| Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M | 1 |
| Hu, C; Luo, R; Wang, Y | 1 |
| Ahn, S; Ha, J; Min, SK; Oh, GT; Song, EJ | 1 |
| Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q | 1 |
3 review(s) available for atorvastatin and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Ceftriaxone; Dibenzazepines; Drug Repositioning; Epilepsy; Epilepsy, Post-Traumatic; Erythropoietin; Fingolimod Hydrochloride; GABA Agents; Gabapentin; Humans; Immunologic Factors; Inflammation; Interleukin 1 Receptor Antagonist Protein; Isoflurane; Levetiracetam; Losartan; Neuroprotective Agents; Oxidative Stress; Pregabalin; Pyrrolidinones; Sirolimus; Stroke; Topiramate; Translational Research, Biomedical; Vigabatrin | 2020 |
4 trial(s) available for atorvastatin and sirolimus
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Topics: Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Everolimus; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Mass Spectrometry; Middle Aged; Pravastatin; Pyrroles; Sirolimus | 2002 |
Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Heptanoic Acids; Humans; Korea; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Single-Blind Method; Sirolimus; Ticlopidine; Time Factors | 2009 |
Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Blood Pressure; Case-Control Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, IGA; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Glomerulus; Male; Middle Aged; Pilot Projects; Prognosis; Prospective Studies; Pyrroles; Sirolimus; Young Adult | 2011 |
Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Everolimus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Prospective Studies; Pyrroles; Sirolimus | 2014 |
19 other study(ies) available for atorvastatin and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Why Some Targets Benefit from beyond Rule of Five Drugs.
Topics: Binding Sites; Drug Discovery; Ligands; Molecular Weight; Protein Binding | 2019 |
Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient.
Topics: Adult; Atorvastatin; Diabetes Mellitus, Type 1; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Islets of Langerhans Transplantation; Pyrroles; Sirolimus | 2003 |
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Echocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphorylation; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Simvastatin; Sirolimus | 2007 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
[Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Female; Heptanoic Acids; Humans; Immunosuppressive Agents; Male; Middle Aged; Pneumonia; Pyrroles; Sirolimus | 2012 |
Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE).
Topics: Animals; Atorvastatin; Blotting, Western; Cytokines; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Female; Flow Cytometry; Heptanoic Acids; Immunologic Factors; Mice; Mice, Inbred C57BL; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sirolimus; Spinal Cord; T-Lymphocytes | 2012 |
In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release.
Topics: Atorvastatin; Calorimetry, Differential Scanning; Cell Proliferation; Cells, Cultured; Drug-Eluting Stents; Heptanoic Acids; Humans; In Vitro Techniques; Microscopy, Electron, Scanning; Molecular Weight; Pyrroles; Sirolimus | 2013 |
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Topics: Animals; Atorvastatin; Caspase 3; Cell Line; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Simvastatin; Sirolimus; TOR Serine-Threonine Kinases; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |
Synergistic therapeutic vascular cytoprotection against complement-mediated injury induced via a PKCα-, AMPK-, and CREB-dependent pathway.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; CD55 Antigens; Complement Activation; Complement System Proteins; Cyclic AMP Response Element-Binding Protein; Cytoprotection; Drug Synergism; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Mice; Protein Kinase C; Pyrroles; Signal Transduction; Sirolimus | 2014 |
Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Atorvastatin; Depression; Disease Models, Animal; Enzyme Inhibitors; Exploratory Behavior; Glycogen Synthase Kinase 3 beta; Hindlimb Suspension; Immunosuppressive Agents; Male; Mice; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2016 |
The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous coronary intervention: an in vitro study.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Senescence; Cytokines; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Harnessing the pleiotropic effects of atorvastatin-fenofibrate combination for cardiovascular stents.
Topics: Animals; Atorvastatin; Calorimetry, Differential Scanning; Cell Adhesion; Cell Line; Cell Proliferation; Cell Survival; Drug-Eluting Stents; Fenofibrate; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Mice; Myocytes, Smooth Muscle; Paclitaxel; Platelet Adhesiveness; Sirolimus; Spectroscopy, Fourier Transform Infrared; Tensile Strength | 2018 |
Heart Valves Cross-Linked with Erythrocyte Membrane Drug-Loaded Nanoparticles as a Biomimetic Strategy for Anti-coagulation, Anti-inflammation, Anti-calcification, and Endothelialization.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cross-Linking Reagents; Endothelial Cells; Erythrocyte Membrane; Heart Valves; Humans; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Sirolimus; Surface Properties | 2020 |
Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cytokines; Disease Models, Animal; Female; Lipid Metabolism; Mice; Mice, Knockout; Renal Insufficiency, Chronic; Sirolimus | 2021 |
Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.
Topics: Atorvastatin; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Humans; Metformin; Percutaneous Coronary Intervention; Risk Factors; Sirolimus; Stents; Treatment Outcome | 2022 |